CYP2C9 genotype | AGTR1 genotype | Reactions for β-receptors blockers | Expected efficacy | Expected adverse reactions | Frequencies | |
---|---|---|---|---|---|---|
Metabolizing capacity | Sensitivity | |||||
*1/*1 | AA | EM | Normal | + | 84.66% (2048) | |
*1/*1 | AC | EM | Slightly increased | ++ | 8.43% (204) | |
*1/*1 | CC | EM | Significantly increased | ++ | 0.21% (5) | |
*1/*3 | AA | IM | Normal | ++ | 5.46% (132) | |
*1/*3 | AC | IM | Slightly increased | +++ | 0.87% (21) | |
*1/*3 | CC | IM | Significantly increased | +++ | + | 0.08% (2) |
*3/*3 | AA | PM | Normal | +++ | 0.29% (7) | |
*3/*3 | AC | PM | Slightly increased | +++ | + | 0 |
*3/*3 | CC | PM | Significantly increased | +++ | ++ | 0 |